Drugs / Tenofovir Alafenamide (TAF)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05423106 Background | Jul 2022 → Mar 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tenofovir Alafenamide (TAF) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05423106 ↗ |
| Known as | TAF | “Tenofovir Alafenamide (TAF)” NCT05423106 ↗ |
| Route | Oral | “TAF tablet will be administered orally.” NCT05423106 ↗ |